Core Viewpoint - The European Medicines Agency has recommended the approval of a subcutaneous version of Sanofi's blood cancer drug, which will be administered through an on-body injector [1] Group 1 - Sanofi is a French drugmaker [1] - The recommended approval pertains to a new formulation of a blood cancer drug [1] - The drug will be delivered using an innovative on-body injector [1]